Valneva Strengthens Management Team; Appoints Perry Celentano as Interim COO and David Lawrence as Acting CFO

Nachrichtenquelle: globenewswire
11.01.2021, 07:00  |  261   |   |   

Saint-Herblain (France), January 11, 2021Valneva SE a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced it has appointed Perry Celentano as Chief Operating Officer (COO) on an interim basis to support the expansion of the manufacturing sites in Livingston and Solna.

Perry Celentano has an extensive track record in the pharma and vaccines industry including roles with Merck, Novartis and Dynavax. Perry will be based at the Company’s Livingston site where the primary production of VLA2001 is taking place. The Company also manufactures its JEV and chikungunya vaccines in Livingston.

Further to the recent announcement that David Lawrence, CFO, will retire at the end of 2020, the Company has re-appointed David as Acting Chief Financial Officer (CFO) potentially until mid-2021. David will support the ongoing strategic planning, including Investor Relations, as well as key collaborations, including the COVID vaccine collaboration with the UK Government. The Company had previously announced that David would support the CEO in an advisory capacity in 2021 following his retirement.

Commenting, Thomas Lingelbach, CEO, said, “Valneva is going from strength to strength and it’s important that we continue to build our senior management team. I am delighted to welcome Perry on board; he is a really strong operations and manufacturing expert and leader. He will play a vital role in the execution of our manufacturing strategy for our planned COVID-19 vaccine. I’m also really pleased that David has agreed to continue helping Valneva and to work with me personally on our near-term objectives. He knows the Company and our investors very well, so will play a pivotal role in executing on our capital formation and growth strategies. These appointments also give the Company time to find the best permanent candidates as we go through an important stage of our evolution.”

About Valneva SE
Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis and DUKORAL indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including unique vaccines against Lyme disease, chikungunya and COVID-19. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 500 employees.  

Seite 1 von 4


Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Valneva Strengthens Management Team; Appoints Perry Celentano as Interim COO and David Lawrence as Acting CFO Saint-Herblain (France), January 11, 2021 – Valneva SE a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced it has appointed Perry Celentano as Chief Operating Officer (COO) on an interim basis …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel